中晚期肺癌患者Nanog表达与GP方案化疗效果的关系  

Relationship between effect of GP regimen prognostic significance and Nanog expression in advanced lung cancer

作　　者：骆梅青[1] 卜庆[1] 曹轶林[1] 郑桂银[1] 伍爱华[1] 施朕善[1] 

机构地区：[1]桂林医学院附属医院肿瘤内科,541001

出　　处：《肿瘤研究与临床》2013年第9期609-611,共3页Cancer Research and Clinic

基　　金：广西壮族自治区卫生厅计划课题（Z2011171）

摘　　要：目的探讨中晚期（Ⅲ期和Ⅳ期）非小细胞肺癌（NSCLC）患者Nanog基因和蛋白的表达与GP方案化疗的疗效关系，并分析对生存期的影响。方法选择使用GP方案化疗的晚期NSCLC患者62例，对使用实时定量聚合酶链反应（qRT-PCR）和免疫组织化学两种方法均检测出Nanog阳性表达的肺癌患者进行GP方案治疗的效果进行对比，并对生存期的影响进行统计分析。结果62例中晚期NSCLC中，Nanog基因和蛋白表达呈阳性30例（48．4％），Nanog阳性表达患者的有效率与未表达的患者比较差异有统计学意义（x^2=0．872，P〈0．01）。完全缓解（CR）组的Nanog阳性表达明显低于部分缓解（PR）组和进展（PD）组，32例有效（CR＋PR）患者中Nanog呈阳性表达9例（28．1％），阴性表达23例（71．9％）。而未显效的32例中Nanog呈阳性表达21例（70．0％），阴性表达9例（30．0％）。生存分析显示，Nanog阳性表达的患者5年生存期短于Nanog阴性表达的患者。结论Nanog表达增强可能导致NSCLC患者对GP方案化疗不敏感并导致5年生存期缩短，检测Nanog的表达可为临床制定NSCLC的个体化治疗方案提供依据，并对预测肿瘤的预后提供参考。Objective To evaluate the correlation between the expression level of Nanog gene and clinical outcomes of GP regimen in the advanced non-small cell lung cancer （NSCLC）. Methods 62 patients of NSCLC were treated by GP method, and the outcomes were investiged between Nanog positive and nagetive patients. The expression level of Nanong was evaluated by RT-PCR and immunohistology. Results 30 out of 62 patients （48.4 %） were Nanog positive, 9 patients （28.1%） were Nanog positive, and 23 out of 32 patients were Nanog negative （71.9 %） who have the positive effect （CR＋PR）. However, among 32 treatment nagetive cases, there were 21 cases （70.0 %） who were Nanog positive and 9 cases （30.0 %） were Nanog negatve. Survival analysis showed that 5-years lifetime of Nanog positive patients was shorter than Nanong nagetive patients. Conclusion Nanog overexpression decreases the sensitivity of GP regimen and lifetime of NSCLC patient. Nanog expression level may provide a useful factor for clinical treatment and prognosis of NSCLC patient.

关 键 词：癌 非小细胞肺 NANOG 药物疗法 联合 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]